OTC News Archive
UT Austin OTC pitches vaccine research findings to GlaxoSmithKline
January 9, 2014
Dr. Stephen Trent of UT Austin’s Institute of Cellular and Molecular Biology has pioneered a process for harvesting a component of E. coli bacteria that can be added to vaccines, which catalyzes stronger immune system reactions in patients. OTC is working with Dr. Trent to market this technology to pharmaceutical companies, including GlaxoSmithKline.
Read the full story at BioNews Texas.